GlassScriptPhysician profile
Sujie Tang
NPI 1134302409
$10,376.13
in general payments reported to CMS, 2019-2025
53 companies · $1,149 in 2025
The $1,149 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,076 · 2020: $1,171 · 2021: $1,434 · 2022: $1,114 · 2023: $1,687 · 2024: $1,745 · 2025: $1,149.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,425 · Education: $157.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,424.99 |
| Education | $156.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $1,154.01 | 2019-2025 | Opdivo, Opdualag |
| Exelixis INC. | $889.60 | 2019-2025 | Cabometyx |
| Astellas Pharma US INC | $765.74 | 2019-2025 | Xospata, Vyloy, Xtandi |
| Amgen INC. | $702.43 | 2019-2024 | Evenity, Prolia, Lumakras |
| Pfizer INC. | $650.52 | 2019-2025 | |
| Glaxosmithkline, LLC. | $554.12 | 2020-2025 | Zejula, Ojjaara |
| Seagen INC. | $540.22 | 2019-2025 | Adcetris, Tukysa |
| Lilly USA, LLC | $493.41 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Genentech USA, INC. | $448.15 | 2019-2025 | Tecentriq, Venclexta, Alecensa |
| Astrazeneca Pharmaceuticals LP | $384.44 | 2019-2025 | Tagrisso, Enhertu, Imfinzi |
| Novartis Pharmaceuticals Corporation | $327.85 | 2019-2025 | |
| Genzyme Corporation | $311.22 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $302.97 | 2019-2021 | |
| Daiichi Sankyo INC. | $257.85 | 2020-2025 | Enhertu |
| Puma Biotechnology, INC. | $191.98 | 2019-2021 |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sujie Tang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.